Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer

Trial Profile

A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Niraparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 04 Feb 2019 Status changed from not yet recruiting to recruiting.
    • 11 Jun 2018 New trial record
    • 05 Jun 2018 According to a Tesaro media release, the company announced that it has entered into a clinical collaboration with Genentech, to evaluate the combination of atezolizumab, cobimetinib and niraparib in patients with platinum-sensitive ovarian cancer. This trial will be conducted by Genentech and is expected to begin by the end of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top